Avtor/Urednik		Horvat, Matej; Zadnik, Vesna; Južnič Šetina, Tanja; Boltežar, Lučka; Pahole Goličnik, Jana; Novaković, Srdjan; Jezeršek Novaković, Barbara
Naslov		Diffuse large B-cell lymphoma
Tip		članek
Vol. in št.		Letnik 15, št. 1
Leto izdaje		2018
Obseg		str. 3602-3609
ISSN		1792-1074 - Oncology letters
Jezik		eng
Abstrakt		Treatment with rituximab plus a regimen of cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) for patients with diffuse large B-cell lymphoma (DLBCL) has proven efficacy in clinical trials. The present study investigated its application in clinical practice. This single%center, retrospective database analysis included patients with DLBCL treated at the Slovenian Institute of Oncology Ljubljana between 2004 and 2013. Overall survival (OS) and progression%free survival (PFS) were assessed according to International Prognostic Index (IPI) and revised IPI (R%IPI) categories. Overall, 573 patients with DLBCL were included in the study (median follow%up, 45.3 months; range, 0.1%143.0). Patients were categorized as IPI %low% (n=170; 30%), %low%intermediate% (n=134; 23%), %high%intermediate% (n=129; 23%) and %high% (n=140; 24%) risk. R%IPI groups were indicated with %very good% (n=59; 10%), %good% (n=245; 43%) and %poor% (n=269; 47%) prognosis. Ten%year OS and PFS rates were 51 and 72%, respectively; median OS was 124 months and median PFS was not reached. Ten%year OS rates were 80 and 87% in low%risk and %very good% prognosis groups, respectively, and 30 and 37% in high%risk and poor prognosis patients, respectively. This analysis of patients with DLBCL indicated that many patients treated with R%CHOP and R%CHOP%like regimens in the real%world setting have excellent outcomes.
Proste vsebinske oznake		difuzni velikocelični B limfom klinične študije napovedni dejavniki diffuse large B-cell lymphoma real-world studies prognosis